Bayer Wins a Round in Court, but the Balance Sheet Still Has the Final Say

Bayer's legal team finally has something to celebrate. A St. Louis jury unanimously rejected glyphosate claims brought by three women, dismissing allegations of product defect, fraud and negligence. According to Reuters, it marks the company's first courtroom victory since the US Supreme Court ruled in its favour — a result that could resonate beyond this single case and into settlement talks and other Roundup litigation. Whether it actually does remains an open question.

That verdict landed alongside a third-quarter update that gave investors plenty to chew on. Group revenue for Q3 2026 came in at EUR 10.053 billion, with EBITDA before special items of EUR 1.615 billion. Adjusted earnings per share reached EUR 0.31, though the bottom line showed a net loss of EUR 0.7 billion. Free cash flow was negative at EUR 0.3 billion.

Two Analysts, Two Verdicts

Jefferies kept Bayer at "Hold" with a EUR 46 price target yesterday. Analyst Michael Leuchten flagged positive surprises on sales and adjusted EBITDA but pointed out that core earnings per share fell short of consensus. JPMorgan, by contrast, reaffirmed "Overweight" and a EUR 61 target, with Richard Vosser citing the strength of the pharma business, the EBITDA beat and the more optimistic guidance.

The shares rose 3.7% yesterday, a move Reuters attributed to the better-than-expected performance of the pharmaceuticals division and the upgraded full-year outlook.

Guidance Raised, but Cash Still Flowing Out

Bayer lifted its 2026 group EBITDA guidance before special items to EUR 9.8–10.3 billion, up from a previous range of EUR 9.6–10.1 billion. The free cash flow forecast was also improved — to minus EUR 1.5 to minus EUR 0.5 billion, from minus EUR 2.5 to minus EUR 1.5 billion.

Less cash leaving the building is not the same as cash coming in. That distinction matters, because net financial debt stood at EUR 31.1 billion, with Bayer projecting EUR 28–29 billion by year-end. The pharma division did its part: EBITDA before special items there jumped 23.6% to EUR 1.292 billion, and management named Pharmaceuticals as the group's key growth driver.

The improved cash flow guidance is a step in the right direction, yet it still describes an outflow. Investors waiting for the debt figure to fall on its own steam will need more than a narrower deficit.

A Restructuring Declared Finished — With Caveats

CEO Bill Anderson said yesterday, according to Reuters, that the company's restructuring is complete, and he left a breakup off the agenda for now. That shifts the question for shareholders from structural overhaul to execution. Anderson did note that further headcount reductions could follow over the next three to four years, so "complete" should not be read as "nothing left to change."

What would a genuinely bullish case look like? The operating business hitting its upgraded targets while legal progress steadily reduces uncertainty. Then the valuation would rest on more than Roundup hopes — it would sit on a firmer earnings base. A single jury verdict, after all, settles one set of claims in one courtroom. It does not determine other cases, nor does it guarantee a cheaper settlement.

The next catalyst on the legal front is court approval of the glyphosate settlement package, which Anderson expects before Christmas. An expectation is not an approval. And the next hard checkpoint is the full-year 2026 results in February 2027, when it becomes clear whether the operating improvement translated into the financial relief management has promised. For now, the courtroom win and the guidance hike are separate pieces of the same investment case — neither one carries it alone.